相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件:
Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
- 英文名:
MMAE-d8;Monomethyl auristatin E-d8;Deuterated labeled MMAE
- 库存:
99
- 供应商:
爱必信(上海)生物科技有限公司
- CAS号:
2070009-72-0
- 规格:
5mg/1mg
| 规格: | 5mg | 产品价格: | ¥33075.0 |
|---|---|---|---|
| 规格: | 1mg | 产品价格: | ¥14553.0 |
| 公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
抑制剂描述: 产品名称:D8-MMAE 产品别名:见爱必信官网 英文别名:D8-MMAE 靶点:Microtubule/Tubulin;ADC Cytotoxin CAS:2070009-72-0 纯度:98% 外观:见爱必信官网 保存方法:Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. 描述:D8-MMAE is a deuterated labeled MMAE, a potent mitotic inhibitor. 溶解性:DMSO : 100 mg/mL (137.74 mM; Need ultrasonic) 体外研究: Antibody-drug conjugates (ADC) comprise targeting antibodies armed with potent small-molecule payloads. ADCs are generated to target different receptors on the anaplastic large cell lymphoma line L-82, but delivered the same cytotoxic payload (monomethyl auristatin E, MMAE), and the intracellular concentration of released MMAE correlated with in vitro ADC-mediated cytotoxicity independent of target expression or drug:antibody ratios. LC-MS is used to measure the concentration of MMAE in a parallel cohort of L-82 tumors with an identical treatment regimen. Although tumor volume is not different among treatment groups 3 days after dose, the intratumoral MMAE measurement reveals two patterns. First, intratumoral MMAE concentration increases proportionally to the ADC dose, which correspondes to stronger antitumor activity. Second, the intratumoral MMAE concentration obtained from treatment with both cOKT9-vcMMAE and cAC10-vcMMAE is similar at each dose, consistent with the observation that tumor responded similarly to these two ADCs. 体内研究:Intratumoral MMAE concentrations consistently correlates with the extent of tumor growth inhibition in tumor xenograft models. IHC analysis reveals that nonbinding control-treated tumors consist of both CD30+ and CD30-cells, presumably because they do not kill either CD30+ or CD30- Karpas 299 cells. Only CD30- cells are found in cAC10-vcMMAF-treated tumors, illustrating that cAC10-vcMMAF eliminates most CD30+ cells. Interestingly, the two tumors that relapses from cAC10-vcMMAE treatment are also found to be CD30- by the end of study, indicating a small fraction of CD30- cells might have escaped from bystander killing in these two remaining tumors.
产品信息订购:
absin,您身边的科研百宝箱 |
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料







